Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma

Teresa Kimlinger, Michael Kline, Shaji K Kumar, John Lust, Thomas Elmer Witzig, S Vincent Rajkumar

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background and Objectives. Bone marrow angiogenesis is increased in patients with multiple myeloma (MM) and correlates with disease stage. Design and Methods. Previous studies of quantifying vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFR) in plasma cells from patients at different stages of MM found no significant difference in expression between overt MM and earlier pre-malignant stages of the disease namely, monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Results. In this report we used quantitative flow cytometry to study cytoplasmic VEGF (cyVEGF) expression (measured as antibody binding capacity) in plasma cells from patients with MM (n=22), MGUS/SMM (n=12), and AL-amyloidosis (AL) (n=9). CyVEGF expression was higher in MM (169,591) than in MGUS/SMM (144,858), or AL (106,011) although these differences were not statistically significant. Using an indirect VEGFR assay that measures VEGF binding, we found VEGF receptors on plasma cells from all groups of patients, with the lowest expression on plasma cells from normal individuals. We detected VEGF R1, VEGF R2, and VEGF R3 on plasma cells from all groups of patients and found receptor expression predominantly in the subset of CD45-positive plasma cells. Interpretation and Conclusions. This study supports the concept that VEGF is involved in the pathogenesis of MM, and suggests that VEGF may differentially affect a subset of plasma cells.

Original languageEnglish (US)
Pages (from-to)1033-1040
Number of pages8
JournalHaematologica
Volume91
Issue number8
StatePublished - Aug 2006

Fingerprint

Vascular Endothelial Growth Factor Receptor
Multiple Myeloma
Vascular Endothelial Growth Factor A
Plasma Cells
Monoclonal Gammopathy of Undetermined Significance
Amyloidosis
Flow Cytometry
Bone Marrow
Antibodies

Keywords

  • CD45
  • Multiple myeloma
  • Plasma cell
  • Vascular endothelial growth factor
  • Vascular endothelial growth factor receptor

ASJC Scopus subject areas

  • Hematology

Cite this

Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma. / Kimlinger, Teresa; Kline, Michael; Kumar, Shaji K; Lust, John; Witzig, Thomas Elmer; Rajkumar, S Vincent.

In: Haematologica, Vol. 91, No. 8, 08.2006, p. 1033-1040.

Research output: Contribution to journalArticle

@article{14f985ee45ad410c87d9f6d7a709fcd0,
title = "Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma",
abstract = "Background and Objectives. Bone marrow angiogenesis is increased in patients with multiple myeloma (MM) and correlates with disease stage. Design and Methods. Previous studies of quantifying vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFR) in plasma cells from patients at different stages of MM found no significant difference in expression between overt MM and earlier pre-malignant stages of the disease namely, monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Results. In this report we used quantitative flow cytometry to study cytoplasmic VEGF (cyVEGF) expression (measured as antibody binding capacity) in plasma cells from patients with MM (n=22), MGUS/SMM (n=12), and AL-amyloidosis (AL) (n=9). CyVEGF expression was higher in MM (169,591) than in MGUS/SMM (144,858), or AL (106,011) although these differences were not statistically significant. Using an indirect VEGFR assay that measures VEGF binding, we found VEGF receptors on plasma cells from all groups of patients, with the lowest expression on plasma cells from normal individuals. We detected VEGF R1, VEGF R2, and VEGF R3 on plasma cells from all groups of patients and found receptor expression predominantly in the subset of CD45-positive plasma cells. Interpretation and Conclusions. This study supports the concept that VEGF is involved in the pathogenesis of MM, and suggests that VEGF may differentially affect a subset of plasma cells.",
keywords = "CD45, Multiple myeloma, Plasma cell, Vascular endothelial growth factor, Vascular endothelial growth factor receptor",
author = "Teresa Kimlinger and Michael Kline and Kumar, {Shaji K} and John Lust and Witzig, {Thomas Elmer} and Rajkumar, {S Vincent}",
year = "2006",
month = "8",
language = "English (US)",
volume = "91",
pages = "1033--1040",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "8",

}

TY - JOUR

T1 - Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma

AU - Kimlinger, Teresa

AU - Kline, Michael

AU - Kumar, Shaji K

AU - Lust, John

AU - Witzig, Thomas Elmer

AU - Rajkumar, S Vincent

PY - 2006/8

Y1 - 2006/8

N2 - Background and Objectives. Bone marrow angiogenesis is increased in patients with multiple myeloma (MM) and correlates with disease stage. Design and Methods. Previous studies of quantifying vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFR) in plasma cells from patients at different stages of MM found no significant difference in expression between overt MM and earlier pre-malignant stages of the disease namely, monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Results. In this report we used quantitative flow cytometry to study cytoplasmic VEGF (cyVEGF) expression (measured as antibody binding capacity) in plasma cells from patients with MM (n=22), MGUS/SMM (n=12), and AL-amyloidosis (AL) (n=9). CyVEGF expression was higher in MM (169,591) than in MGUS/SMM (144,858), or AL (106,011) although these differences were not statistically significant. Using an indirect VEGFR assay that measures VEGF binding, we found VEGF receptors on plasma cells from all groups of patients, with the lowest expression on plasma cells from normal individuals. We detected VEGF R1, VEGF R2, and VEGF R3 on plasma cells from all groups of patients and found receptor expression predominantly in the subset of CD45-positive plasma cells. Interpretation and Conclusions. This study supports the concept that VEGF is involved in the pathogenesis of MM, and suggests that VEGF may differentially affect a subset of plasma cells.

AB - Background and Objectives. Bone marrow angiogenesis is increased in patients with multiple myeloma (MM) and correlates with disease stage. Design and Methods. Previous studies of quantifying vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFR) in plasma cells from patients at different stages of MM found no significant difference in expression between overt MM and earlier pre-malignant stages of the disease namely, monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Results. In this report we used quantitative flow cytometry to study cytoplasmic VEGF (cyVEGF) expression (measured as antibody binding capacity) in plasma cells from patients with MM (n=22), MGUS/SMM (n=12), and AL-amyloidosis (AL) (n=9). CyVEGF expression was higher in MM (169,591) than in MGUS/SMM (144,858), or AL (106,011) although these differences were not statistically significant. Using an indirect VEGFR assay that measures VEGF binding, we found VEGF receptors on plasma cells from all groups of patients, with the lowest expression on plasma cells from normal individuals. We detected VEGF R1, VEGF R2, and VEGF R3 on plasma cells from all groups of patients and found receptor expression predominantly in the subset of CD45-positive plasma cells. Interpretation and Conclusions. This study supports the concept that VEGF is involved in the pathogenesis of MM, and suggests that VEGF may differentially affect a subset of plasma cells.

KW - CD45

KW - Multiple myeloma

KW - Plasma cell

KW - Vascular endothelial growth factor

KW - Vascular endothelial growth factor receptor

UR - http://www.scopus.com/inward/record.url?scp=33746959381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746959381&partnerID=8YFLogxK

M3 - Article

VL - 91

SP - 1033

EP - 1040

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 8

ER -